NDA 021332 · Astrazeneca Ab
Symlin
Pramlintide Acetate · Subcutaneous
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Dec 18, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Mar 16, 2005
Approved uses
2
Original approval plus efficacy supplements
Registered trials
53
8 Phase 3, 1 recruiting
FAERS reports
102
51 serious, 10 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEVERE HYPOGLYCEMIA SYMLIN use with insulin increases the risk of severe hypoglycemia, particularly in patients with type 1 diabetes. When severe hypoglycemia occurs, it is seen within 3 hours following a SYMLIN injection. Serious injuries may occur if severe hypoglycemia occurs while operating a motor vehicle, heavy machinery, or while engaging in other high-risk activities. Appropriate patient selection, careful patient instruction, and insulin dose reduction are critical elements for reducing this risk. WARNING: SEVERE HYPOGLYCEMIA See full prescribing information for complete boxed warning. • SYMLIN use with insulin has been associated with an increased risk of severe hypoglycemia, particularly in patients with type 1 diabetes. • Hypoglycemia risk may be reduced by appropriate patient selection, careful patient instruction, and insulin dose reduction (5.1 , 5.2) .
What it is approved for
From the label in effect Dec 18, 2019.
SYMLIN is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. SYMLIN is an amylin analog indicated for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy (1) .
Mechanism: Pramlintide is an analog of human amylin. Amylin is colocated with insulin in secretory granules and cosecreted with insulin by pancreatic beta cells in response to food intake. Amylin and insulin show similar fasting and postprandial patterns in healthy individuals (Figure 1). Figure 1: Secretion Profile of Amylin and Insulin in Healthy Adults In patients with type 1 and type 2 diabetes, there is reduced secretion from pancreatic beta cells of both insulin and amylin in response to food. Amylin affects the rate of postprandial glucose appearance through a variety of mechanisms, as determined...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 27, 2014 Supplement 7 · Efficacy LetterLabel
- Mar 16, 2005 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
3 products under this application
- SYMLIN · PRAMLINTIDE ACETATE EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued
- SYMLIN · PRAMLINTIDE ACETATE EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued
- SYMLIN · PRAMLINTIDE ACETATE EQ 3MG BASE/5ML (EQ 600MCG BASE/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Pramlintide" as an intervention, any sponsor and status, largest first.
- Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00673387 · 636 participants · Start Apr 2008 · Primary completion Apr 2009
Drug: pramlintide acetate; metreleptin and 2 more · For: Overweight; Obesity
Sites: Birmingham, Alabama; Chandler, Arizona; Santa Rosa, California · 36 sites in all
- Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes MellitusPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00108004 · 400 participants (planned) · Start Apr 2003 · Primary completion Jun 2005
Drug: pramlintide acetate · For: Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus
Sites: Anaheim, California; Escondido, California; La Jolla, California · 48 sites in all
- A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese SubjectsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00112021 · 400 participants · Start May 2005 · Primary completion Nov 2005
Drug: pramlintide acetate · For: Obesity
Sites: Chula Vista, California; San Diego, California; Walnut Creek, California · 21 sites in all
- Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose ControlPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00042458 · 296 participants · Start Apr 2002 · Primary completion Mar 2003
Drug: Pramlintide acetate; Placebo · For: Diabetes Mellitus, Type 1
Sites: Mesa, Arizona; Phoenix, Arizona; Concord, California · 33 sites in all
- Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With MetreleptinPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00819234 · 274 participants · Start Nov 2008 · Primary completion Oct 2009
Drug: Placebo; Pramlintide and Metreleptin · For: Obesity
Sites: Birmingham, Alabama; Phoenix, Arkansas; Santa Rosa, California · 33 sites in all
- A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese SubjectsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00402077 · 258 participants · Start Nov 2006 · Primary completion Aug 2007
Drug: pramlintide acetate; sibutramine and 2 more · For: Overweight; Obesity
Sites: Birmingham, Alabama; Phoenix, Arizona; Chula Vista, California · 16 sites in all
- A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese SubjectsPivotal-lookingTerminated
AstraZenecaAstraZeneca (AZN)
NCT01235741 · 213 participants · Start Jan 2011 · Primary completion Sep 2011
Drug: Pramlintide+Metreleptin; Placebo · For: Obesity
Sites: Greenbrae, California; La Jolla, California; Denver, Colorado · 18 sites in all
- A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese SubjectsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00189514 · 210 participants · Start Sep 2005 · Primary completion Jun 2007
Drug: pramlintide acetate; placebo · For: Obesity
Sites: Chula Vista, California; San Diego, California; Walnut Creek, California · 21 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased15
- acute kidney injury11
- chronic kidney disease11
- nausea9
- dyspnoea8
- fatigue8
- hypertension7
- renal failure7
- weight decreased7
- chest pain6
- diarrhoea6
- drug ineffective6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 5 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 9 |
| 2013 | 8 |
| 2014 | 8 |
| 2015 | 11 |
| 2016 | 13 |
| 2017 | 5 |
| 2018 | 9 |
| 2019 | 10 |
| 2020 | 8 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.
Galderisi A, Sherr J, VanName M, et al. · J Clin Endocrinol Metab 2018 · Clinical Trial, Research Support, N.I.H., Extramural
- Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes.
Hinshaw L, Schiavon M, Dadlani V, et al. · J Clin Endocrinol Metab 2016 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients.
Ghanizada H, Al-Karagholi MA, Walker CS, et al. · Ann Neurol 2021 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Pramlintide in the treatment of diabetes.
Edelman SV, Darsow T, Frias JP · Int J Clin Pract 2006 · Randomized Controlled Trial
- Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets.
Hollander P, Ratner R, Fineman M, et al. · Diabetes Obes Metab 2003 · Meta-Analysis
- Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.
Kong MF, King P, Macdonald IA, et al. · Diabetologia 1997 · Clinical Trial, Comparative Study
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.